CLBT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

126.07M

+15.61%

0.139

+39.36%

125.20M

+16.41%

0.110

+9.8%

131.33M

+15.94%

0.124

+3.58%

Estimates Revision

The market is revising Upward the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by 5.51%.

Revenue Estimates for FY2025

Revise Upward

+0.63%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.1%

In Past 3 Month

Stock Price

Go Up

+5.51%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.83 USD with a low forecast of 23.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 18.390

Low

23.00

Averages

24.83

High

28.00

Current: 18.390

Low

23.00

Averages

24.83

High

28.00

JPMorgan

Brian Essex

Overweight

maintain

$23 -> $24

2025-11-13

Reason

JPMorgan

Brian Essex

Price Target

$23 -> $24

2025-11-13

maintain

Overweight

Reason

JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $24 from $23 and keeps an Overweight rating on the shares. The company reported solid Q3 results with "multiple levers" to drive growth in 2026, the analyst tells investors in a research note.

BofA

Buy

maintain

$24 -> $25

2025-11-13

Reason

BofA

Price Target

$24 -> $25

2025-11-13

maintain

Buy

Reason

BofA raised the firm's price target on Cellebrite to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company's Q3 report.

Lake Street

Buy

maintain

$22 -> $23

2025-11-13

Reason

Lake Street

Price Target

$22 -> $23

2025-11-13

maintain

Buy

Reason

Lake Street raised the firm's price target on Cellebrite to $23 from $22 and keeps a Buy rating on the shares. The firm was "pleased to see Cellebrite get back on track" following what it calls out as "two consecutive quarters of disappointment." The firm, which raised its 2025 estimates, tells investors that the strength in U.S. state and local and LATAM have it "feeling more confident the business is back on the right track."

JPMorgan

Brian Essex

Overweight

maintain

$20 -> $23

2025-09-24

Reason

JPMorgan

Brian Essex

Price Target

$20 -> $23

2025-09-24

maintain

Overweight

Reason

JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $23 from $20 and keeps an Overweight rating on the shares. The firm updated security software models post the earnings reports. The results reflect a stable to improving macro environment for security software, the analyst tells investors in a research note. The firm says companies exposed to large enterprise budgets and high priority spending categories are better positioned. It added Varonis Systems (VRNS) to JPMorgan Analyst Focus List and reiterated Cellebrite (CLBT) as a focus list pick.

Lake Street

Eric Martinuzzi

Buy

downgrade

$24 -> $22

2025-08-15

Reason

Lake Street

Eric Martinuzzi

Price Target

$24 -> $22

2025-08-15

downgrade

Buy

Reason

Lake Street analyst Eric Martinuzzi lowered the firm's price target on Cellebrite to $22 from $24 and keeps a Buy rating on the shares. Slower-moving Q1 deals in Europe came through in Q2, but the U.S. federal softness persisted in Q2 and is "not expected to break loose until October," the analyst tells investors in a post-earnings note. The federal issue will lower 2025 revenue more than originally expected, so the firm is trimming its estimates, the analyst added.

BofA

analyst

Buy

downgrade

$25 -> $24

2025-08-14

Reason

BofA

analyst

Price Target

$25 -> $24

2025-08-14

downgrade

Buy

Reason

BofA lowered the firm's price target on Cellebrite to $24 from $25 and keeps a Buy rating on the shares. Q2 results and second half guidance were below Street expectations on lasting DOGE efficiency impacts and budget pauses, but "the good news is that it is only a matter of timing," says the analyst, who believes the company should obtain FedRAMP High ATO status by the first half of 2026, further supporting cloud growth in Federal.

Valuation Metrics

The current forward P/E ratio for Cellebrite DI Ltd (CLBT.O) is 35.77, compared to its 5-year average forward P/E of 46.66. For a more detailed relative valuation and DCF analysis to assess Cellebrite DI Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

46.66

Current PE

35.77

Overvalued PE

70.16

Undervalued PE

23.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

26.61

Current EV/EBITDA

28.38

Overvalued EV/EBITDA

39.18

Undervalued EV/EBITDA

14.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.36

Current PS

8.73

Overvalued PS

7.83

Undervalued PS

2.89

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLBT News & Events

Events Timeline

No data

News

7.5

12-10NASDAQ.COM

Norwood Investment Partners Establishes New $4.3 Million Stake in Cellebrite

8.5

12-02Newsfilter

Cellebrite Acquires Corellium for $170 Million, Enhancing Digital Investigation Capabilities

2.0

11-18Benzinga

This Week's Fast-Growing Tech Stocks See Significant Increases in Growth Ratings

People Also Watch

Frequently Asked Questions

What is Cellebrite DI Ltd (CLBT) stock price today?

The current price of CLBT is 18.39 USD — it has decreased -2.28 % in the last trading day.

What is Cellebrite DI Ltd (CLBT)'s business?

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

What is the price predicton of CLBT Stock?

What is Cellebrite DI Ltd (CLBT)'s revenue for the last quarter?

Cellebrite DI Ltd revenue for the last quarter amounts to 126.03M USD, increased 17.94 % YoY.

What is Cellebrite DI Ltd (CLBT)'s earnings per share (EPS) for the last quarter?

Cellebrite DI Ltd. EPS for the last quarter amounts to 0.08 USD, decreased -108.08 % YoY.

What changes have occurred in the market's expectations for Cellebrite DI Ltd (CLBT)'s fundamentals?

How many employees does Cellebrite DI Ltd (CLBT). have?

Cellebrite DI Ltd (CLBT) has 1167 emplpoyees as of December 15 2025.

What is Cellebrite DI Ltd (CLBT) market cap?

Today CLBT has the market capitalization of 4.60B USD.